Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.

Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved ...

Eli Lilly (LLY) stock in focus as eczema therapy Ebglyss lead to complete skin clearance in 50% of subjects in a long-term ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Feetures, America's #1 running sock, is dedicated to supporting athletes of all ages and promoting the importance of being ...

Lebrikizumab (Ebglyss) also targets IL-13 and is approved to treat moderate to severe eczema in adults and children 12 years and older. Nemolizumab (Nemluvio) targets IL-31, which seems to be ...

Tampa General Hospital (TGH) has again been named the top hospital in Tampa Bay and one of the top 100 hospitals in the United States, according to Newsweek's "World's Best Hospitals 2025" rankings.

MicroStrategy’s Andrew Kang talks about bitcoin holdings, Krispy Kreme’s Jeremiah Ashukian discusses business model changes ...